Table 2 Baseline Fibroscan results.

From: Utility of Fibroscan XL to assess the severity of non-alcoholic fatty liver disease in patients undergoing bariatric surgery

Fibroscan Data

Baseline (n = 167)

Steatosis CAP (dB/m)a (dB/m)

291.4 (± 58.8)

 Grade 0

37 (22%)

 Grade 1

36 (22%)

 Grade 2

35 (21%)

 Grade 3 (severe)

59 (35%)

Significant steatosis (≥ S1)

130 (78%)

Fibrosis LSM (kPa)b

5.1 (± 1.9)

 Stage 0 (≤ 6.5 kPa)

145 (87%)

 Stage 1

12 (7%)

 Stage 2

3 (2%)

Advanced Fibrosis (3–4)

7 (4%)

Significant fibrosis (≥ F2)

10 (6%)

  1. Results expressed as mean (± SD) or frequency (percentage).
  2. aCAP = Controlled attenuation parameter steatosis grades: 0 (nil significant) < 248 dB/m; 1 (mild) 248–280 dB/m; 2 (moderate) = 281-319 dB/m; 3 (severe) > 320 dB/m.
  3. bLSM = Liver stiffness measurement fibrosis stages: 0 (no significant fibrosis) ≤ 6.5 kPa; 1 (mild) 6.6–8.2 kPa; 2 (significant) > 8.2–9.6 kPa; 3–4 (advanced) > 9.6 kPa.
Back to article page